The association of hepatic glycogenosis with Fanconi syndrome was first described in 1949 (10) . Thirteen such cases have so far been reported (1, 2, 4, 5, 11, 12, 17, 20, 22, 23) . In addition to the normal features of the Fanconi syndrome (phosphoglucoaminoaciduria, vitamin D resistant rickets and growth retardation) and unclassified glycogen storage disease, patients exhibit disturbed responses to carbohydrate loading, especially major impairment of galactose utilization.
The aim of this paper is to report the results of metabolic studies of a patient with hepatic glycogenosis and Fanconi syndrome, and to demonstrate the presence of abnormal galactose oxidation.
CASE REPORT
The propositus, a 5-year-old Algerian girl, was admitted for evaluation of a presumptive Fanconi syndrome with glycogen storage disease (GSD). She was born after a full term pregnancy of healthy consanguineous parents and had two healthy siblings. Her height was 81 cm (-6 S.D.) and her weight was 1 1 kg (-3 S.D.). She was extremely hypotonic and exhibited severe rickets. She had not yet begun to walk. Her abdomen was protuberant and a soft liver edge was easily palpable 5 cm below the costal margin.
Laboratory investigations revealed proximal tubular dysfunction (Table I) . Serum cholesterol was 6.40 mmole/liter and her triglycerides level 3.43 mmole/liter. Standard liver function tests were normal. Slit lamp examination of both eyes did not reveal cystine crystals. X-ray examination showed active rickets and osteoporosis. 15 The patient's diet was supplemented with 25-OH-cholecalciferol, phosphorus, calcium, and bicarbonate. With this treatment, the serum phosphate concentration increased, but remained between 0.8 and 1.0 mmole/liter, whereas the plasma carbon dioxide level returned to normal (18-22 mmole/liter). Rickets was only partially controlled.
METHODS
All studies of the patient and of the subjects who served as controls were undertaken after obtaining parental or personal consent.
In vivo studies. Metabolic and hormonal responses were determined under normal dietary conditions, and during a 24-h fast. Stimulation tests were performed with glucagon, glucose, galactose, and fructose.
Specific enzymatic techniques were used to measure the concentration of blood glucose, galactose, fructose, lactate, pyruvate, P-hydroxybutyrate, and acetoacetate. Serum phosphate was evaluated by colorimetric assay. Plasma free fatty acids were assayed by gas phase chromatography. Plasma insulin and cortisol were determined by radioimmunoassays.
In vitro studies. Blood samples and surgical liver specimens were taken after an overnight fast. Blood samples were collected in heparinized tubes and studied immediately. Control samples came from adult subjects with no hematological disorders.
Part of the liver tissue samples was divided into aliquots, which were immediately frozen in liquid nitrogen. The remainder was placed in ice cold normal saline and ragidly brought to the laboratory. Oxidation experiments with [I-' Clgalactose were performed on fresh liver tissue within 30 min of biopsy. Enzyme assays were carried out on frozen tissue, after 15 days at most of storage at -180°C (enzyme activities were shown to be stable under these conditions). Controls were liver specimens obtained during laparotomy for abdominal pathology without liver failure.
Glycogenolysis. The activity of phosphorylase kinase (EC 2.7.1.38) and of amylo-l,6-glucosidase (EC 3.2.1.33) was assayed in hemolysates (I 8) .
The glycogen content and the respective activities of glucose 6-phosphatase (EC 3.1.39) and amylo-l,6-glucosidase (EC 3.2.1.33), phosphorylase (EC 2.4.1. I), and phosphoglucomutase (EC 2.7.5.1) were determined in liver homogenates (14) .
Galactose metabolism. The following enzyme assays were performed. Galactokinase (EC 2.7.1.6), uridyltransferase (EC 2.7.7.12), and UDP-glucose 4-epimerase (EC 5.1.3.2) activities were assayed in hemolysates and liver supernatants after centrifugation of the crude homogenates at 12,000 x g for 20 min. red cell transferase activity was determined by the UDP-glucose consumption method of Beutler and Baluda (6) . Liver uridyltransferase activity was measured by the method of Segal et al. (24) . (3) UDP-glucose 4-epimerase assay: to determine this activity in both red cells and liver, a spectrophotometric assay with a twostep procedure was used (13) .
The in vitro production of radioactive carbon dioxide from [I-'4C]galactose by intact red blood cells and minced liver tissue was measured. Incubations were carried out in Warburg flasks, with Krebs-Ringer bicarbonate buffer (KRB), gassed with combined O2 and COz to obtain a pH of 7.4. A removable plastic cup containing 0.2 ml of 5.4 mole/liter KOH was positioned on top of the center well for C 0 2 collection. At the end of incubation, 0.4 ml of 6 mole/liter was poured from the side-arm into the medium, and the flasks were mechanically shaken for 1 h at room temperature. One-tenth ml of [I4C02] trapped in KOH was then transferred into a counting vial, with 4 ml of methoxy ethanol and 9 ml of scintillation fluid (5.5 g/liter PPO in toluene) and counted in a liquid scintillation spectrometer.
A blank without the cell preparation was included in each series of experiments. The propositus and one control were tested simultaneously.
Intact erythrocytes: the incubation medium consisted of 1. Other determinations. he hemoglobin content of hemolysates was determined by a modified Drabkin procedure (27) .
Proteins in liver homogenates and supernatants were assayed by Lowry's method (19) .
RESULTS
In vivo studies, basal studies ( Fig. 1 and Fig. 2 ). Under normal dietary conditions, blood glucose, insulin and cortisol values varied within the normal range. However, the blood lactate concentration increased after 2 meals. Fractional sampling of urine showed permanent glucosuria, even when the blood glucose concentration fell to 2.4 mmole/liter.
During the 24 hour-fast, concentrations of blood glucose, lactate, P-hydroxybutyrate, free fatty acids and plasma insulin, remained within the normal range, as did the lactate to pyruvate and P-hydroxybutyrate to acetoacetate ratios (Table 2) . 
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Glucose (mmol/l) - (Fig. 3). (1) Two hours after a meal, a definite rise in blood glucose was observed, with a concomitant drop in blood lactate. (2) After an overnight fast, blood glucose only rose slightly and blood lactate remained unchanged. During the 2 h after glucagon injection, the glucosuria was 21.3 mmole versus 6.3 mmole during the 2 h before injection. There was no significant change in the lactate to pyruvate or /3-hydroxybutyrate to acetoacetate ratios during this test ( Table 2) .
The results of the carbohydrate loading test are as follows. (I) Oral administration of glucose (Fig. 4) was followed by a large increase in the blood glucose concentration. A return to basal level was only observed 3 h after ingestion. Blood insulin-toglucose ratios remained within the normal range as did the blood lactate-to-pyruvate and P-hydroxybutyrate to acetoacetate ratios ( Table 2) . (2) After I.V. administration of glucose (Fig. 4) , a slow decline in the blood glucose concentration was noted, together T~r n e (rnin) with massive glucosuria (16 mmoles during the I-h postinjection period). (3) After I.V. administration of fructose, blood glucose values rose less significantly than in control subjects (21) , and changes in the blood lactate and serum phosphate values were found to be within the normal range (Fig. 5) . (4) I.V. administration of galactose (I g/kg) was followed by persistent galactosemia with no significant variations in blood glucose or lactate levels (Fig. 5) . (5) After I.V. galactose administration of 0.35 g/kg, the half-life (t %) of the injected product was 16.5 min (normal range at the patient's age: 6.5 + 1.5 (16)), and about 50% of the dose administered was recovered as galactosuria.
There was no significant change in the lactate to pyruvate or P-hydroxybutyrate to acetoacetate ratios during the test (Table 2) .
In vitro studies, glycogenolysis ( Table 3) . Increased liver glycogen content was observed, but no deficiency of glucose 6-phosphatase, amylo-l,6-glucosidase, phosphorylase or phosphoglucomutase activities were found in liver homogenates.
Normal activity was also found in hemolysates for phosphorylase kinase, and amylo-1,6-glucosidase.
In vitro studies, galactose metabolism (Table 4) . Erythrocytes: normal activity was found in hemolysates for galactokinase, uridyltransferase and UDP-glucose 4-epimerase. [I-14C]galactose oxidation by intact red blood cells was also shown to be within the normal range.
Liver tissue: activity was normal for the galactose metabolic pathway enzymes (galactokinase, uridyltransferase and UDP-glucose 4-epimerase) in the patient's liver supernatants, whereas significant impairment of [I-'4C]galactose oxidation was observed in minced liver tissue. DISCUSSION Our patient had an unclassified form of GSD associated with a Fanconi syndrome. As previously described in other patients with a similar condition, she displayed massive glucosuria, partial resistance to glucagon stimulation, and abnormal responses to carbohydrate loading, which was mainly a major impairment of galactose utilization.
Persistent galactosemia after galactose administration is very 11.
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I.V. injection of glucagon after an overnight fast (1 mg/m2) Per os glucose loading I.V. injection of galactose (30 g/m2) (0.35 g/kg) ' Preliminary personal studies and data from the literature (25) showed that adult levels are reached at 5% years, for all parameters assayed. This is why the patient's results were compared to adult controls.
Only adult control subjects were tested, in cases when the values in the literature (24) were identical for children and adults.
unusual in cases where liver G S D is not associated with a Fanconi syndrome. On the other hand, Chesney et al. (7, 8) described a similar abnormality in three subjects with idiopathic Fanconi syndrome but no liver disease. Increased blood lactate to pyruvate ratios were also present in these three patients, suggesting an altered redox state. This last phenomenon might be involved in the defective galactose utilization, through a mechanism of UDPglucose 4-epimerase inhibition due to an increased NADH to NAD ratio. and the tricarboxylic cycle. As the patient's in vivo galactoseglucose interconversion was impaired, the metabolic defect seems to have occurred between the time when galactose enters the hepatocyte and when glucose is released from glucose 6-phosphate. Assays of phosphoglucomutase and glucose 6-phosphatase activities in a liver homogenate from the patient were normal. Consequently, the possibility of a metabolic disturbance of the hepatic galactose pathway itself was investigated. Normal activity was found for the patient's liver galactokinase, uridyltransferase, and UDP-glucose 4-epimerase. Her defective hepatic galactose oxidation was therefore not connected with any in vitro deficiency of the key galactose metabolic pathway enzymes, so that two alternative possibilities were considered.
The first idea envisaged was impaired galactose transport across the liver cells. Little information is at present available on this transport mechanism in man, and one can only argue by analogy with what has been demonstrated in certain mammalian species like sheep and rat, thus, in the rat, galactose is transferred across the hepatocytes by mediated diffusion. But its carrier is not specific but is common to all the hexoses with graduated affinities: Dglucose, D-galactose, and D-fructose with KM of 30 mmole/liter, 100 mmole/liter and > 100 mmole/liter, respectively (3, 9) . The significance of this mediated diffusion mechanism is not known for physiologic circulating hexose concentrations, which are far below the KM given above. Consequently, it is impossible to tell whether an abnormality in mediated hexose diffusion would have repercussions on hexose utilization. No abnormality of this type has yet been described. In our patient, we observed that poor in vivo galactose utilization was accompanied by slightly perturbed fructose utilization. The existence of a non-specific abnormality affecting hexose penetration into the liver was earlier mentioned by Odiivre (20) The second possible explanation for defective galactose oxidation might be a dysregulation of the hepatic galactose pathway. But the absence in the propositus of clinical manifestations like those observed in subjects with deficient galactokinase, uridyltransferase or UDP-glucose Cepimerase activities (IS) argues against this hypothesis.
The abnormality observed in our patient is apparently the second localized abnormality to be described for galactose rnetabolism, the first being an UDP-glucose 4-epimerase defect restricted to red and white blood cells, with no clinical signs (13) . Further investigations are required to confirm that defective hexose transport across the liver cell is indeed involved in this type of disorder, rather than a specific disturbance in galactose metabolism
